Clinical Trials
Company-Supported Clinical Trials
Key clinical trials sponsored by Mallinckrodt for branded drugs are listed on www.clinicaltrials.gov and detailed below, with a link provided to learn more and an indicator of the current phase of development.
| Study Title | PHASE 1 | PHASE 2 | PHASE 3 | PHASE 4 |
|---|---|---|---|---|
| Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria (PODOCYTE) More Information (MNK14224049) > |
X | |||
| Acthar Gel for Active Systemic Lupus Erythematosus (SLE) More Information (MNK14304067) > |
X | |||
| Acthar Gel in Participants With Pulmonary Sarcoidosis (PULSAR) More Information (MNK14344100) > |
X | |||
| Impact of Acthar on Everyday Life of Participants With Severe Keratitis More Information (MNK14084113) > |
X | |||
| Registry to Evaluate INOmax in Newborn Babies with Pulmonary Hypertension (PaTTerN) More Information (MNK19050056) > |
X | |||
| A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin (CONFIRM) More Information (MNK19013058) > |
X | |||
| Adrabetadex for Patients With Nerve Symptoms of Niemann-Pick Type C Disease (NPC) More Information (VTS-270-001) > |
X | |||
| MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function More Information (MNK61053106) > |
X | |||
| StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements More Information (STRATA2016) > |
X | |||
| Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1 More Information (VTS-270-302) > |
X | X | ||
| VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease More Information (VTS301) > |
X | X | ||
| MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) More Information (MNK61062107) > |
X | |||
| ExpressGraft-C9T1 Skin Tissue as a Treatment of Diabetic Foot Ulcers More Information (C9T12015) > |
X | |||
| Multiple Applications of ExpressGraft-C9T1 Skin Tissue as a Treatment for Diabetic Foot Ulcers More Information [C9T12015 (Extended)] > |
X | |||
| Follow up Study of Patients Having Participated in Clinical Trial 64,185-204 (JASMINE_205) More Information (64,185-205) > |